B+
Bull case
20%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-03-15 · RankAlpha Sentiment AI
AVD
American VanguardBNYSE / Materials
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
50%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-03-15 · RankAlpha Sentiment AI
B-
Bear case
30%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-03-15 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-03-15
Recent news sentiment (30D)
+23.3
Positive
Company
-
Unavailable
Macro
+23.3
Positive
Pulse
-
Unavailable
Weekly research (10D)
-45.0
Negative
Sentiment proxy
+100.0
Score
AI commentary
Market commentary is mixed: analysts' median target implies substantial upside relative to the current anchor price, but public disclosure of near-term operational detail is limited to standard filings and quarterly results [#10-K-2025-05-29] [#8-K-2025-11-12]. Recent IR/news schedules an earnings release on 2026-03-16 that is the nearest actionable read for investors [#IR-undated] .
RankAlpha Sentiment AI - 2026-03-15
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; rating conviction does not match the scenario target upside
Impact
degraded
Confidence
-
AI events
2026-03-16eventFull-year 2025 results / earnings release and webcastHigh impact
Company scheduled to release full-year 2025 results and host a webcast on 2026-03-16; market reaction likely around guidance/comments and any updated capital-allocation commentary [#IR-undated] (prior interim results were disclosed via 8-K Item 2.02) [#8-K-2025-11-12].
2027-03-15catalystEarnings/operational recovery drives re-rating toward analyst medianHigh impact
If FY2025 results and subsequent quarters show margin or EBITDA improvement consistent with prior strategic targets disclosed in filings and IR, shares could re-rate toward analyst median/consensus (~$11); prior filings include the 2025 10-K and recent 8-K results disclosures which provide the baseline to monitor for improvement [#10-K-2025-05-29] [#8-K-2025-11-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-03-15 • Updated nightlySource: Internal modelMethodology